Capital Efficiency Isn't a Defensive Posture. It's a Power Move.

• Capital efficiency has flipped from survival tactic to competitive advantage. Investors are rewarding founders who arrive with pilots, milestones, and paying customers.

• "Intentional" beats "lean." Investors want founders who can articulate exactly what each dollar unlocked, not just that they kept the burn low.

• Information management debt is a silent killer that tanks credibility.

• Non-dilutive funding signals you can build. Revenue signals the market is responding.

• The 2020 to 2022 hangover is still reshaping valuations. "Execution," says one investor, "is the only currency that translates into future funding."

“Across every Capital Readiness cohort, we hear the same thing from investors,” says Science Center President and CEO Tiffany Wilson. “The founders worth backing have already done the work – non-dilutive funding exhausted, pilots in market, milestones hit on their own dime. Capital efficiency isn’t what they’re settling for. It’s what they’re being rewarded for.”

For years, running lean in early-stage health and life sciences meant one thing: survival. You managed burn because the alternative was running out. That's changing. The founders winning investment today aren't just leaner — they're more deliberate, arriving at investor conversations with evidence, pilots, and in some cases paying customers. That changes what the conversation looks like. And who has the leverage in it.

We spoke with three investors — Adrianna Samaniego of Cherryrock Capital, Maren Nelson of the Alliance of Angels, and Erica Murdock of Unseen powered by Seae Ventures — about what capital discipline actually looks like from the other side of the table. Here's what they told us.

Intentional, Not Just Lean

Ask investors what they're actually looking for in a capital efficiency story, and the answer isn't a number. It's a narrative.

“I'm not looking for lean-by-necessity," says Adrianna Samaniego, Partner at Cherryrock Capital. "I'm looking for intentional." When a founder has raised significant capital, Samaniego wants a crisp account of what each tranche unlocked — what the last round de-risked, what it proved. "If a founder can't answer that cleanly, that tells me more about how they'll deploy my capital than any burn chart does." She's also watching for how founders are thinking about AI as a force multiplier. The bar for what a lean team can accomplish has shifted, she notes, and founders who are actively using AI to extend their leverage look meaningfully different from those who aren't. "More is getting done with less," she says. "So I'm also asking how they're thinking about that. It shows up in both burn and output."

For Erica Murdock, Managing Partner of Unseen powered by Seae Ventures, the proof is in the data room itself. A capital-efficient company, she argues, can demonstrate it because they're already tracking it. "When we dig into a data room, we're asking a specific set of questions: How are you monitoring operational spend? What do your gross margins look like over time? How are you managing COGS relative to resource costs?" The tell, she says, is in the use of funds. "A capital-efficient team knows exactly how the next dollar accelerates to a specific milestone. An underfunded team's use of funds reads more like catch-up."

The discipline shows up even earlier — in how founders sequence their development work. For Maren Nelson, Co-Chair of the Life Sciences Screening Committee at Alliance of Angels, that starts long before a data room is ever opened. Efficient founders do risk management first, not last. They use inspection, analysis, and demonstration before defaulting to expensive full-prototype verification. They design clinical trials to cover multiple endpoints rather than running sequential studies. "It requires some extra thought up front," Nelson says, "but it's way less expensive than multiple trials."

The Debt Nobody Talks About

Every investor raised a version of the same concern: capital efficiency taken too far, or practiced in the wrong places, creates debt that doesn't surface until it's expensive to fix.

The most familiar form is technical debt. But Nelson introduced a category that rarely appears in investor conversations: information management debt. Medical companies, she observes, focus on managing quality system documentation but neglect the broader product development history — decisions made, specifications updated, validation results and the conditions under which they were achieved. "The results can be the need for repeat validation and verification, inability to repeat successful results, or lack of credibility for investors because the wrong pitch deck was pulled."

Murdock takes a portfolio management approach to the problem. "While it's impossible to completely avoid some degree of technical, regulatory, or clinical debt, having the right resources in place early can help limit the amount accumulated over time." Her team checks in with portfolio companies regularly — better to flag early and develop a mitigation plan, she says, than to be blindsided at a later stage.

Samaniego frames it as a growth question. The company that looks capital-efficient because it has never stress-tested distribution worries her. "Clean burn, small team, solid product — sometimes that's discipline, sometimes that's avoidance. I want to see that they've spent money trying to grow and learned something from it, not just that they've successfully deferred the hard part."

What Non-Dilutive Capital Actually Signals

All three investors value non-dilutive funding — but for reasons that go beyond the dollars themselves.

For Samaniego, the weight she assigns non-dilutive funding depends on context. In sectors where grants represent genuine third-party validation, she takes them seriously. "If a company is winning NIH grants or SBIR funding, that's fantastic — it's non-trivial validation from a rigorous, competitive process and it signals the science is credible." Outside of those sectors, she says, the structure of the financing matters less than the thinking behind it. "I care more about the decision behind the financing choice than the structure itself."

Murdock draws a careful distinction between what non-dilutive capital proves and what it doesn't. "Non-dilutive capital tells us a company can build. Traction tells us the market is responding." Grants alone don't close the loop — she still needs to see evidence of commercial momentum alongside them. Interestingly, she also encourages portfolio companies to pursue non-dilutive funding after receiving VC backing, using it to test product innovation and explore adjacent workflows without putting core KPIs at risk.

Nelson is direct about the limits: non-dilutive funding is excellent for product development, but a company relying primarily on it raises questions about its ability to fund administrative and operational costs. The grant-dependent company, in other words, may be technically de-risked but operationally underdeveloped.

Revenue Changes the Room

When founders arrive with paying customers, something shifts, though perhaps not in the ways founders expect.

"Customer revenue remains one of the highest-value signals we see at the seed stage, which has a real impact on valuation," says Murdock. But she's careful to qualify it: "Revenue without a credible growth story only goes so far." Signed LOIs, she adds, speak to pipeline strength rather than valuation. “They signal intent, not conversion, and we weigh them accordingly.”

Nelson agrees that revenue changes conviction, with one important caveat: context matters enormously. "$70K for a company that got FDA clearance six months ago is very different than $70K for a company that got clearance five years ago," she says. "And I've seen both."

The deeper point all three investors circle back to is this: revenue is leverage, but only when it's paired with a credible narrative about where it's going. The founders who understand that aren't just better positioned for their current raise. They're building the kind of companies that can choose their investors rather than the other way around.

Execution Is the Only Currency That Translates

The 2020 to 2022 funding environment inflated valuations, accelerated timelines, and in some cases rewarded founders for raising more than they needed. Investors today are navigating the hangover — and not everyone agrees on what it means.

"I'm not sure the market 'rewarded' it," says Nelson, "but the company value expectations set during that time were not in line with what I typically look at for investments." Her message to founders is pointed: equivalent companies with lower valuations will often get more funding than those holding onto inflated numbers, regardless of underlying quality.

Murdock is more direct about the dynamic. "The harder question is whether founders are being asked to correct a problem they didn't create. While most made sound decisions with their capital and find themselves navigating a much different market, others overcapitalized carelessly." What's different now, she says, is that the margin for error is thinner and the consequences are clearer. "The market that funded your early bets has changed, and execution is the only currency that translates into future funding."

Samaniego zooms out to the round cycle itself — and what it demands of founders who want to survive it. Companies are staying private longer, she notes, which means the capital raised has to genuinely work. "You don't get to bridge to the next milestone in 18 months if the market isn't there." And with exit multiples increasingly tied to EBITDA, the discipline founders build at the earliest stages has a longer shadow than many realize. "Even at an early stage, I want to see that founders understand the levers — how to improve gross margins, where the fat is, how to make each dollar productive." The round cycles are longer now. The margin for imprecision has narrowed accordingly.

The environment is harder. The bar is higher. But for the founders who treated discipline as a strategy long before the market demanded it, that bar is exactly where they want it. Clearing it is the point.